Ozanimod beats placebo for ulcerative colitis

(HealthDay)—For patients with moderately to severely active ulcerative colitis, ozanimod is more effective than placebo as induction and maintenance therapy, according to a study published in the Sept. 30 issue of the New ...


Drug boosts survival for women with advanced ovarian cancer

Women with advanced ovarian cancer often face grim statistics, with less than half surviving for five years after their diagnosis. However, a new study suggests that so-called "maintenance therapy" with a targeted cancer ...

Oncology & Cancer

Niraparib extends time without symptoms in ovarian cancer

(HealthDay)—Women with recurrent ovarian cancer who receive the poly ADP ribose polymerase (PARP) inhibitor niraparib as maintenance therapy after treatment have both more time without side effects and significantly longer ...

page 1 from 4